Despite variability in cohort composition, transplant protocols, and outcome reporting, our systematic review highlights the heterogeneous clinical course of GATA2-MDS/AML and reinforces HSCT as the cornerstone of treatment. Here, GATA2 is linked to acute myeloid leukemia.